VASO Restructures to Focus on Congestive Heart Failure

May 5, 2005 12:18 PM EDT

Vasomedical, Inc. (NASDAQ: VASO) announced an initiative to improve alignment of operations to pursue the congestive heart failure market. This initiative, which includes a workforce reduction plus tighter expense control, is expected to provide a clear focus on CHF investment and to reduce expenses by approximately $3 million over the next year.


Related Categories

Corporate News

Stocks Mentioned

VASO 0.24

+0.00 +0.00%
Volume: 18,140
Track VASO


Add Your Comment





Follow StreetInsider.com On Twitter